Evidence map›Paper›PMID 41400139›Full record

ArticleFEBS letters2026

Function-driven design of a surrogate interleukin-2 receptor ligand.

Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziwei TangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Zelin ChengShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Teng LiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Fulian WangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Liangminghui ZhangInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, China.
Xiuxiu HeInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, China.
Lili LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Wei WangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.
Aibin LiangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Guang YangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, China.ORCID https://orcid.org/0000-0001-7379-6810

Funding

Jiangsu Basic Research Center for Synthetic Biology BK20233003Ministry of Science and Technology of China fund 2021YFA1100800Shanghai Municipal Education Commission (SMEC) grant to the Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at the ShanghaiTech University
6 · The paper itself

Abstract

Interleukin (IL) receptors play a pivotal role in immune regulation through coordinated interactions among multiple receptor subunits. Their cognate ligands, interleukins, orchestrate diverse immune responses by engaging distinct subunit combinations. Here, we developed a programmable IL-2 receptor surrogate ligand using a combinatorial bispecific agonist antibody strategy. By employing two complementary cell-based reporter systems that simultaneously monitor IL-2 receptor-mediated STAT5 activation and cell proliferation, we engineered a surrogate IL-2 receptor ligand that exhibits biased activation and differentiation of effector T and NK cells. This modular approach enables the development of tailored cytokine receptor surrogates with customized immunomodulatory functions.

Indexed as

Receptors, Interleukin-2AnimalsAntibodies, BispecificCell DifferentiationCell ProliferationHEK293 CellsHumansKiller Cells, NaturalLigandsSTAT5 Transcription FactorT-LymphocytesAntibodies, BispecificLigandsReceptors, Interleukin-2STAT5 Transcription Factorbiologycell biologycell growtheffectorimmune receptorimmune systeminterleukin

Identifiers

PMID41400139
PMCPMC13113230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.